Genevoyager Plans for the Construction of New Gene Therapy CDMO Facility in USA
Introduction:
Genevoyager unveils state-of-the-art gene therapy contract development and manufacturing organisation (CDMO) facility in USA.
Features:
The newly inaugurated cGMP facility boasts state-of-the-art infrastructure, featuring its proprietary One-Bac 4.0 system integrated with the Sf-RVF® cell line.
The purpose-built facility covering an 68,000 square feet is designed to streamline the process of developing, manufacturing, and scaling AAV gene therapy products.
Its design and infrastructure are tailored specifically to support the seamless progression of these therapies from concept to market, ensuring efficient production and adherence to regulatory standards throughout every stage of the process.
With the operation of this advanced facility, comprehensive development and manufacturing services will be offered for AAV, lentivirus, oncolytic viruses, and recombinant proteins.
This diverse range of capabilities enables the provision of tailored solutions to advance innovative biologics from conception to commercialisation, serving the needs across various therapeutic areas.
Specifications:
Name Genevoyager
Type New Construction
